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eIF4E Is an Adverse Prognostic Marker of Melanoma
Patient Survival by Increasing Melanoma Cell Invasion
Shahram Khosravi1,2, Kevin J. Tam2, Gholamreza S. Ardekani1, Magdalena Martinka3, Kevin J. McElwee1 and
Christopher J. Ong2
Human cutaneous melanoma is a devastating skin cancer because of its invasive nature and high metastatic
potential. We used tissue microarray to study the role of human eukaryotic translation initiation factor 4E (eIF4E)
in melanoma progression in 448 melanocytic lesions and found that high eIF4E expression was significantly
increased in primary melanomas compared with dysplastic nevi (Po0.001), and further increased in metastatic
melanomas (Po0.001). High eIF4E expression was associated with melanoma thickness (P¼ 0.046), and poor
overall and disease-specific 5-year survival of all, and primary melanoma patients, especially those with tumors
Z1mm thick. Multivariate Cox regression analysis revealed that eIF4E is an independent prognostic marker. eIF4E
knockdown (KD) in melanoma cells resulted in a significant increase in apoptosis (sub-G1 populations) and
decrease in cell proliferation, and also resulted in downregulation of mesenchymal markers and upregulation of
E-cadherin. In addition, eIF4E KD led to a decrease in melanoma cell invasion, matrix metalloproteinase-2
expression and activity, c-myc and BCL2 expression, and an increase in cleaved PARP and cleaved caspase-3
expression and chemosensitivity. Taken together, our data suggest that the eIF4E may promote melanoma cell
invasion and metastasis, and may also serve as a promising prognostic marker and a potential therapeutic target
for melanoma.
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INTRODUCTION
Human cutaneous melanoma is resistant to conventional
radio- and chemotherapy (Gray-Schopfer et al., 2007), and
is responsible for the deaths of 480% of skin cancer patients
(Miller and Mihm, 2006).
The eukaryotic translation initiation factor 4E (eIF4E) is a
potent oncogene that has elevated expression in many human
cancers, including carcinomas of the breast, prostate, lung,
head and neck, bladder, cervix, nasopharynx, as well as in
many leukemias and lymphomas (De Benedetti and Graff,
2004; Hariri et al., 2013; Wu et al., 2013). eIF4E elevation
leads to increased proliferation, evasion of apoptosis,
oncogenic transformation, tumor invasion, and metastases
(De Benedetti and Rhoads, 1990; Lazaris-Karatzas et al.,
1990; Graff et al., 1995; Polunovsky et al., 1996; Borden
and Culjkovic-Kraljacic, 2010).
In tumors, eIF4E concentrations are elevated by the
activation of the mammalian target of rapamycin pathway.
Mammalian target of rapamycin phosphorylates 4EBP1, which
leads to disengagement of 4EBP1 from eIF4E and disinhibition
of translation by increasing the availability of eIF4E (Sun et al.,
2005). eIF4E depletion in cancer cells, on the other hand,
leads to cell cycle arrest and decreased tumorigenicity (Kentsis
et al., 2004; Oridate et al., 2005; Graff et al., 2007; Assouline
et al., 2009). In melanoma, using immunohistochemistry in
the tissue array research program (TARP) tissue microarray
(TMA) revealed that eIF4E was elevated in 59% of the 23
melanoma tissue cores that were used for the analysis (Yang
et al., 2007).
We showed that eIF4E is an independent prognostic marker
that may promote melanoma cell invasion and metastasis, and
its increased expression predicts a worse survival in melanoma
patients.
RESULTS
eIF4E expression correlates with melanoma tumor thickness and
AJCC stages
Melanocytic lesions in a total of 713 patients were used to
construct the TMA. Because of the loss of biopsy cores, loss of
follow up or insufficient tumor cells present in the cores, 381
melanoma (238 primary and 143 metastatic melanoma cases)
and 67 nevi cases (28 common acquired and 39 dysplastic
nevi) could be evaluated for eIF4E staining (Supplementary
Figure S1 online). Supplementary Table S1 online includes a
list of the clinical features of the melanoma patients. As
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thickness is a well-known prognostic marker for primary
melanoma patients, we analyzed the eIF4E expression level
in tumors with different thicknesses. High eIF4E expression
was found in 86.3% of thick melanomas (Z1 mm) compared
with 75% of thin melanomas (o1 mm) (P¼0.046, w2 test;
Supplementary Table S1 online), indicating that within pri-
mary melanoma eIF4E expression is likely induced during the
transition from thin to thick melanoma. In addition, high eIF4E
expression was significantly more common in advanced stage
melanomas (AJCC stages III and IV) compared with early-stage
melanomas (AJCC stages I and II) (P¼ 0.002, w2 test;
Supplementary Table S1 online). The correlation of high eIF4E
expression with tumor thickness and AJCC stages suggests that
eIF4E may have an important role in melanoma invasion.
eIF4E expression is increased with melanoma progression
We performed immunohistochemical staining in TMA slides
(Figure 1a–h) and categorized the samples into low and high
eIF4E expression. A significant increase in the expression of
eIF4E was detected with the progression of melanoma from
dysplastic nevi to primary melanoma and from primary
melanoma to metastatic melanoma (Po0.001 and
P¼0.008, respectively, w2 test; Figure 1i and Supplementary
Figure S2 online), suggesting that increased eIF4E expression
might be a critical requirement for the transformation from
nevus to malignant tumor and also for the development of
melanoma metastasis. We also examined the expression
pattern of eIF4E in six melanoma cell lines compared with
melanocytes. At least in five of the cell lines, eIF4E protein
expression increased compared with melanocytes (Figure 1j).
Increased eIF4E expression is associated with poor patient
survival
Kaplan–Meier survival analysis showed that, relative to low
eIF4E expression, high eIF4E expression inversely correlated
with overall and disease-specific 5-year survival in all
(Po0.001, log rank test; Figure 2a and b) and in primary
melanoma patients (P¼0.027 and 0.022, respectively, log
rank test; Figure 2c and d). As the expression of eIF4E is
increased from thin (o1 mm) to thick (Z1 mm) melanomas
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Figure 1. Eukaryotic translation initiation factor 4E (eIF4E) protein expression in different melanoma stages and in melanoma cell lines compared with normal
human melanocytes. Representative images of eIF4E immunohistochemical staining in melanocytic lesions. (a–d) Bar ¼ 100mm. (e–h) Bar ¼ 10mm. (a and e)
Negative eIF4E staining. (b and f) Weak eIF4E staining. (c and g) Moderate eIF4E staining. (d and h) Strong eIF4E staining. (i) eIF4E expression is increased in MM
compared with CAN (Po0.001, w2 test), DN (Po0.001, w2 test), and PM (P¼0.008, w2 test). eIF4E expression is also increased in PM compared with CAN and DN
(Po0.001, w2 test). (j) Western blot analysis of eIF4E in whole-cell extracts from melanoma cell lines and melanocytes. CAN, common acquired nevi; DN,
dysplastic nevi; MC, melanocyte; MM, metastatic melanoma; PM, primary melanoma.
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(Supplementary Table S1 online), the difference in patient
survival between the two groups was examined next.
Supplementary Figure S3 online shows that primary mela-
noma patients with tumors Z1 mm thick had a significantly
less overall and disease-specific 5-year survival compared
with patients with tumors o1 mm thick (P¼0.001, log rank
test). When eIF4E expression was included in the analysis, a
significant difference was observed in survival of patients with
tumors Z1 mm thick, with high eIF4E expression being
associated with a poorer survival outcome (P¼ 0.021 and
0.024 for overall and disease-specific survival, respectively,
log rank test; Figure 2e and f). However, no correlation
between eIF4E expression and patient survival was observed
for tumors o1 mm thick (data not shown).
eIF4E is an independent prognostic marker for melanoma
patients
Univariate Cox proportional hazard regression analysis sup-
ported the results from the Kaplan–Meier survival analysis by
showing that high eIF4E expression was a significant prog-
nostic factor for the overall and disease-specific 5-year
survival of all melanoma patients (hazard ratio (HR): 3.20,
95% confidence interval (CI): 1.63–6.26, P¼0.001 and HR:
4.33, 95% CI: 1.91–9.80, Po0.001, respectively;
Supplementary Table S2 online), primary melanoma patients
(HR: 2.69, 95% CI: 1.08–6.70, P¼0.033 and HR: 3.59, 95%
CI: 1.12–11.52, P¼ 0.032, respectively; Supplementary Table
S2 online), and primary melanoma patients with tumors
Z1 mm thick (HR: 3.59, 95% CI: 1.12–11.47, P¼0.031 and
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Figure 2. Kaplan–Meier curves representing the correlation between eukaryotic translation initiation factor 4E (eIF4E) expression and 5-year survival of
melanoma patients. (a and b) Increased eIF4E expression is associated with poor overall and disease-specific 5-year survival in all melanoma patients (Po0.001,
log rank test). (c and d) Increased eIF4E expression is associated with poor overall and disease-specific 5-year survival in primary melanoma patients (P¼ 0.027 and
0.022, respectively, log rank test). (e and f) Increased eIF4E expression is associated with poor overall and disease-specific 5-year survival in primary melanoma
patients with tumors Z1 mm thick (P¼ 0.021 and 0.024, respectively, log rank test). Cum., cumulative.
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HR: 4.44, 95% CI: 1.08–18.29, P¼0.039, respectively;
Supplementary Table S3 online).
Further, multivariate Cox regression analysis indicated that
eIF4E was an adverse independent prognostic factor for the
overall and disease-specific 5-year survival of all melanoma
patients (HR: 2.39, 95% CI: 1.21–4.69, P¼0.012 and HR:
3.09, 95% CI: 1.36–7.03, P¼ 0.007, respectively;
Supplementary Table S4 online), primary melanoma patients
(HR: 2.72, 95% CI: 1.08–6.87, P¼0.034 and HR: 3.47, 95%
CI: 1.06–11.29, P¼ 0.039, respectively; Supplementary Table
S4 online), and primary melanoma patients with tumors
Z1 mm thick (HR: 3.85, 95% CI: 1.19–12.45, P¼0.024 and
HR: 4.59, 95% CI: 1.10–19.17, P¼0.037, respectively;
Supplementary Table S4 online).
eIF4E regulates cell invasion via MMP-2 expression and activity
Our TMA results suggested the importance of high eIF4E
expression for the development of melanoma metastasis and
also indicated an inverse correlation between high eIF4E
expression and patient survival. Consequently, we decided
to study the role of eIF4E in increasing melanoma cell
invasion, which is one of the hallmarks of cancer and leads
to higher metastatic potential of melanoma and decreased
survival of melanoma patients (Friedl and Wolf, 2003). We
used eIF4E-specific small interfering RNA (siRNA) to knock
down eIF4E expression and found that cell invasion was
significantly reduced in eIF4E-KD MMRU and MMLH cells
compared with control siRNA-transfected cells (P¼ 0.022 and
0.026, respectively, t-test; Figure 3a and c, respectively).
Likewise, the use of a second eIF4E-specific siRNA
(sieIF4E-1) in MMRU cells confirmed our results (P¼ 0.017,
t-test; Supplementary Figure S4a online). As matrix metallo-
proteinase (MMP-2) is known to have an important role in cell
invasion (Vaisanen et al., 1996; Li et al., 2008), we next
performed zymography assay and western blot analysis, and
observed a decrease in the gelatinolytic activity and
expression of MMP-2 in eIF4E-KD MMRU and MMLH cells
compared with their respective controls (Figure 3b and d,
respectively). A similar result was obtained using sieIF4E-1 in
the MMRU cell line (Supplementary Figure S4b online). In
order to further support our findings, we used a mammalian
target of rapamycin inhibitor called rapamycin, which is able
to suppress 4EBP1 phosphorylation and consequently lead to
inhibition of eIF4E (Yellen et al., 2011). MMRU cells were
exposed to 0% serum and treated with DMSO or 2mM
rapamycin (Yellen et al., 2011) for a total of 36 hours.
Twelve hours after the start of the treatment, cells were
subjected to Boyden chamber assay. A significant reduction
in invasion was observed in rapamycin-treated cells compared
with DMSO-treated cells (Supplementary Figure S4c online).
Zymography assay and western blot analysis also showed a
decrease in MMP-2 activity and expression, respectively, in
rapamycin-treated cells compared with the control group
(Supplementary Figure S4d online). Our previous TMA study
examining the expression of MMP-2 in melanoma showed
that MMP-2 expression is a prognostic marker for melanoma
patients (Rotte et al., 2012). Analysis of the 372 melanoma
biopsies in common between the MMP-2 study and the
current study indicated a direct association between high
eIF4E and strong MMP-2 expression (Po0.001, w2 test;
Figure 4a).
We further divided the samples into four groups on the basis
of their staining: (1) low eIF4E expression and negative-
moderate MMP-2 expression; (2) either low eIF4E expression
and strong MMP-2 expression or high eIF4E expression and
negative-moderate MMP-2 expression; and (3) high eIF4E
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Figure 3. Eukaryotic translation initiation factor 4E (eIF4E) knockdown inhibits melanoma cell invasion by reducing matrix metalloproteinase 2 (MMP-2)
expression and activity. MMRU (left column) and MMLH (right column) melanoma cell lines were transfected with eIF4E-specific siRNA (sieIF4E) or control small
interfering RNA (siRNA) for two consecutive times, with the second time being 48 hours after the first. (a and c) For Boyden chamber assay, 72 hours after the first
transfection, cells were suspended in a serum-free medium, seeded on matrigel, incubated at 37 1C for 24 hours, stained, and quantified. Top, representative
images of invaded cells in the insets of Transwell chambers. Bottom, quantification of cell invasion. *Po0.05, Student’s t-test. (b and d) Protein extracts were
prepared 96 hours after the first transfection and analyzed by western blotting. Matrix metalloproteinase 2 (MMP-2) activity was determined by zymography
96 hours after the first transfection.
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expression and strong MMP-2 expression. For both all
(Figure 4b and c) and primary melanoma (Figure 4d and e)
patients, those classified as category 1 had the most and the
ones classified as category 3 had the least favorable survival
outcome, and survival rate for patients in category 2 was
between the other two categories (Po0.001 for overall and
disease-specific 5-year survival of all and primary melanoma
patients, log rank test; Figure 4b–e).
eIF4E KD increases apoptosis and decreases cell proliferation in
melanoma cell lines
To knock down eIF4E, we transiently transfected MMRU and
MMLH melanoma cells with sieIF4E or non-silencing control
siRNA twice consecutively, with the second transfection time
being 48 hours after the first one. At 96 hours after first
transfection, cells were collected for western blot analysis.
Consistent with findings in prostate cancer (Graff et al., 2009),
reduced eIF4E protein expression resulted in suppression of
BCL2 expression, which is an eIF4E-regulated protein, and an
increase in the expression of other apoptosis markers such as
cleaved caspase-3 and cleaved PARP in both MMRU and
MMLH melanoma cell lines (Figure 5a and d, respectively).
The expression level of c-myc, which is a known eIF4E-
regulated protein and controls both proliferation and apoptosis
(Jamerson et al., 2000), was also decreased along with
reduced eIF4E expression in MMRU and MMLH cell lines
(Figure 5a and d, respectively). We next evaluated the
biological consequences of reducing eIF4E expression in
melanoma cells. At 48, 72, and 96 hours after first transfection,
cells were collected for proliferation assay. eIF4E KD led to a
continuous significant decrease in cell proliferation in MMRU
and MMLH melanoma cell lines, from 48 to 96 hours after the
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and in (d and e) primary melanoma patients (Po0.001 for both overall and disease-specific 5-year survival of all and primary melanoma patients, log rank test).
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first transfection, as indicated by sulforhodamine B-cell pro-
liferation assay (Figure 5b and e, respectively). As the biggest
difference in cell proliferation happened 96 hours after the first
transfection, this time point was chosen for apoptosis assay.
eIF4E KD induced apoptosis as evidenced by significantly
increased sub-G1 populations in the KD groups compared
with the control groups in MMRU and MMLH melanoma cell
lines (P¼0.003 and Po0.001, respectively, t-test; Figure 5c
and f, respectively). All of the above results were confirmed by
using sieIF4E-1 in MMRU melanoma cell line (Supplementary
Figure S5a–c online). Treatment of MMRU cells with rapamy-
cin, as explained before, also resulted in a decrease in the
expression of c-myc and BCL2, and an increase in the
expression of cleaved caspase-3 and cleaved PARP in the
rapamycin-treated cells compared with the control
(Supplementary Figure S5d online). In addition, rapamycin
treatment of MMRU cells led to a significant decrease and
increase in cell proliferation and apoptosis, respectively
(Supplementary Figure S5e and f online).
eIF4E may have a role in inducing epithelial–mesenchymal
transition
In order to investigate the role of eIF4E in inducing epithelial–
mesenchymal transition (EMT), western blot analysis was
performed. eIF4E KD resulted in a downregulation of
mesenchymal markers such as vimentin, N-cadherin, and
a-smooth muscle actin, and an upregulation of E-cadherin
epithelial marker, compared with the vector control, in
MMRU and MMLH melanoma cells. eIF4E KD also led to a
downregulation of Twist, the EMT inducing transcription
factor, in MMRU cells, but Twist was not detected in MMLH
melanoma cells (Supplementary Figure S6a and b online,
respectively). These findings suggest that eIF4E may have a
role in the induction of EMT, which supports the possible role
of eIF4E in invasion and metastasis.
eIF4E KD increases chemosensitivity of melanoma cell lines
A major obstacle of melanoma treatment is its resistance to
drug-induced apoptosis. As increased eIF4E expression
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Figure 5. Eukaryotic translation initiation factor 4E (eIF4E) knockdown promotes apoptosis and inhibits cell proliferation in melanoma cells. MMRU (left
column) and MMLH (right column) melanoma cells were transfected with eIF4E-specific siRNA (sieIF4E) or control small interfering RNA (siRNA) for two
consecutive times, with the second time being 48 hours after the first. (a and d) Ninety-six hours after the first transfection, protein extracts were analyzed by
western blotting. (b and e) Fourty-eight, 72, and 96 hours after the first transfection, cell proliferation was analyzed by sulforhodamine B assay. *Po0.05 and
**Po0.01, Student’s t-test. (c and f) Ninety-six hours after the first transfection, cells were stained with propidium iodide and the percentage of apoptotic (sub-G1)
cells was measured by flow cytometry. Top, quantification of apoptotic cells. Bottom, representative FACS images. **Po0.01 and ***Po0.001, Student’s t-test.
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strongly correlates with poor patient survival, we investigated
the involvement of eIF4E in chemoresistance of melanoma
cells. As above, we twice transfected MMRU and MMLH
melanoma cell lines with sieIF4E or control siRNA. At
72 hours after the first transfection, cells were treated with
0.25mg/ml doxorubicin for 24 hours (Lin et al., 2009).
Proliferation of cells after simultaneous eIF4E KD and
doxorubicin treatment was significantly lower compared
with those of cells simultaneously treated with control
siRNA and doxorubicin in MMRU and MMLH cells
(P¼ 0.015 and Po0.001, respectively, t-test; Figure 6a and
b, respectively). We next performed flow cytometric analysis
and showed that drug-treated cells with eIF4E KD have higher
sub-G1 populations compared with the cells treated with
control siRNA and doxorubicin in MMRU and MMLH cells
(P¼ 0.031 and 0.021, respectively, t-test; Figure 6c and d,
respectively). Similarly, cisplatin-treated eIF4E KD MMRU
cells showed higher level of apoptosis and lower level of
proliferation compared with cells simultaneously treated with
control siRNA and cisplatin (Supplementary Figure S7 online).
This might be an indication that perhaps eIF4E downregulation
in melanoma cells increases drug-induced apoptosis, suggest-
ing that melanoma resistance to chemotherapy may in part be
due to an increase in eIF4E protein expression.
DISCUSSION
Similar to our results, colon and prostate TMAs showed eIF4E
as an indicator of tumor progression and poor prognosis of
patients (Graff et al., 2009; Niu et al., 2014). One plausible
explanation for the negative correlation between eIF4E
expression and 5-year survival of melanoma patients could
be a role for eIF4E in regulating the proliferation and apoptosis
of melanoma cells. Inhibition of eIF4E by siRNA or rapamycin
in our study substantially inhibited the proliferation of
melanoma cells and c-myc expression, which further
suggests a role for eIF4E in increasing melanoma cell
proliferation, as c-myc has been shown to be important for
cell proliferation and growth (Jamerson et al., 2000).
Consistent with our findings, overexpression of eIF4E in
CHO or CREF cells yielded increased c-myc expression (De
Benedetti and Harris, 1999). In addition, by looking at the
subG1 populations, we found that eIF4E inhibition induced
apoptosis in melanoma cells. Our results further supported this
by showing a downregulation in BCL2 expression and an
increase in cleaved caspase-3 and cleaved PARP expression as
a result of eIF4E inhibition. Consistently, it has been
demonstrated that reduced eIF4E expression in prostate and
breast cancer cell lines and xenografts repressed expression of
eIF4E-regulated proteins, such as c-myc and BCL2, reduced
cellular proliferation, inhibited the growth of cancer
xenografts in mice with minimal toxicity, and induced
apoptosis, as evidenced by an increase in cleaved caspase-
3, and an overall reduction in cell number (Graff et al., 2007;
Graff et al., 2009). Similarly, elevated expression of cleaved
PARP has previously been detected in non-small cell lung
carcinoma cells transfected with eIF4E siRNA (Li et al., 2012).
The above suggests that downregulation of eIF4E may inhibit
the growth of cancer cells through both proliferation down-
regulation and apoptosis upregulation. Because of the lack of
information about the genetic mutations of our cohort, we
were unfortunately unable to correlate eIF4E expression with
mutations such as BRAF or NRAS. However, the unpublished
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sequencing data from our lab show that the MMRU melanoma
cell line carries the BRAFV600E mutation.
Furthermore, eIF4E inhibition led to a decrease in the
expression and gelatinolytic activity of MMP-2, which may
be a contributing factor to the elevated invasiveness of
melanoma cells. These data are supported by observing the
direct correlation between high expression of eIF4E and strong
expression of MMP-2 in our TMA, which also helps explain
the TMA results showing a correlation between melanoma
thickness and eIF4E expression, and consequently a correla-
tion between eIF4E expression and reduced 5-year survival of
primary melanoma patients. In addition, our finding that
concurrent higher expression of both eIF4E and MMP-2
(category 3) was associated with the worst survival outcome
compared with lower expression of either eIF4E or MMP-2
(category 2) (Figure 4b–e) provides a rationale for dual
therapeutic targeting of eIF4E and MMP-2 in melanoma.
The importance of MMP-2 in melanoma progression has
been shown before. The increase in atypia in different stages
of melanoma is accompanied by an increase in the number of
MMP-2-positive cells (Vaisanen et al., 1996). Changes in
MMP-2 expression and activity can be controlled through
different ways. For instance, the mitogen-activated protein
kinase signaling pathway has been shown to regulate MMP2
expression via p38 mitogen-activated protein kinase, ERK1/2,
and JNK/c-Jun (Simon et al., 1998; Westermarck and Kahari,
1999; Johansson et al., 2000; Zhu et al., 2013). Membrane
type 1 MMP creates active MMP-2 by cleaving pro-MMP-2,
and membrane type 1 MMP itself can be induced by the
transcription factor NF-kB (Sato et al., 1994), a target of p-AKT
(Dhawan et al., 2002). Skp2 is another oncogene whose
mRNA translation depends on eIF4E and is required for
oncogenesis and exiting contact inhibition (Nogueira et al.,
2012). MMP-2 activity and expression were shown to increase
because of an increase in Skp2 expression in lung cancer
(Hung et al., 2010).
Confirming our TMA and in vitro results, eIF4E has been
shown to promote invasion and EMT in other cancers, as well.
For example, Shankar et al. (2010) reported the transcriptome/
proteome analysis of six metastatic cell lines of varying tumor
origin, including the breast, prostate, fibrosarcoma, and
glioma, and identified eIF4E as one of the proteins whose
expression is critical for pseudopod protrusion, actin
cytoskeleton dynamics, and tumor cell migration and
invasion. Interestingly, loss of eIF4E reversed EMT in these
highly metastatic cell lines and resulted in cell–cell interac-
tion, expression of E-cadherin, and reduced migration and
invasion (Shankar et al., 2010). Others have attempted to
design compounds to inhibit eIF4E and prevent it from
triggering EMT (Ghosh et al., 2009). Effect of eIF4E on
vimentin protein expression has also been observed before.
Hsieh et al. (2012) generated a human prostate cancer cell
line that stably expresses a mutant form of 4EBP1, which binds
to eIF4E and decreases its hyperactivation. Their experiments
showed a decrease in vimentin protein on induction of this
mutant (Hsieh et al., 2012). However, our study needs further
support from in vivo animal studies to fully delineate the role
of eIF4E in the multi-step invasion–metastasis cascade.
Melanoma is particularly resistant to conventional therapies
(Tarhini and Agarwala, 2006). We showed that eIF4E KD
increases chemosensitivity of melanoma cells to doxorubicin
and cisplatin. This could be because many chemotherapeutic
agents induce apoptosis, whereas disruption of apoptosis
during tumor evolution can promote drug resistance
(Johnstone et al., 2002; Minotti et al., 2004). As we and
others have shown, eIF4E has anti-apoptotic activities (Lazaris-
Karatzas et al., 1990; Polunovsky et al., 2000), therefore, eIF4E
ablation might restore sensitivity to chemotherapy. The role of
eIF4E in increasing chemoresistance has been previously
demonstrated. In the Em-myc transgenic B-cell lymphoma
mouse model, eIF4E overexpression accelerates lympho-
magenesis (Ruggero et al., 2004; Wendel et al., 2004) and
causes resistance to doxorubicin (Wendel et al., 2004). In lung
cancer, however, elevated eIF4E contributes to the
development of erlotinib resistance, likely through positive
regulation of c-Met expression (Li et al., 2012).
In summary, we found that increased eIF4E expression is
significantly correlated with melanoma progression and a
worse 5-year survival of patients, especially those with
tumor thickness of Z1mm. Furthermore, our data suggest that
eIF4E is an independent prognostic factor that has a
role in EMT and regulating melanoma cell invasion, pro-
liferation, apoptosis, and chemoresistance. All these, plus the
fact that reducing eIF4E expression in other cancers has
been shown to suppress tumor growth without having any
deleterious effects on normal tissues (Graff et al., 2007), make
eIF4E a potentially very good target candidate for melanoma
therapy.
MATERIALS AND METHODS
Patients and specimens
Formalin-fixed, paraffin-embedded tissues from a total of 448 mela-
noma patients were used. All specimens were obtained from the 1990
to 1998 archives of the Department of Pathology, Vancouver General
Hospital. The use of human skin tissues in this study was approved by
the Clinical Research Ethics Board of the University of British
Columbia and was performed in accordance with the Declaration
of Helsinki Principles. Patient consent was not required under
Canadian law, as this was a retrospective study using anonymized
data and many patients have already died. Details are available in
Supplementary Methods online.
TMA construction and immunohistochemistry of TMA
TMA construction and immunohistochemical staining were per-
formed as previously described (Dai et al., 2005; Zhang et al.,
2011), using rabbit primary antibody against eIF4E (1:75 dilution;
Santa Cruz Biotechnology, Santa Cruz, CA).
Evaluation of immunostaining
Samples were grouped into low and high eIF4E expression. Details
are available in Supplementary Methods online.
Statistical analysis
The w2 test, Kaplan–Meier method, univariate and multivariate Cox
proportional hazards regression models, and Student’s t-test were
used as previously described (Chen et al., 2012).
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Cell culture and transfection
Human melanoma cell lines MMRU and MMLH were cultured as
previously described (Lu et al., 2013). For siRNA transfection, cells
were incubated with either non-silencing control siRNA or two
distinct sieIF4E (SI00300125 and sieIF4E-1, SI03155733, Qiagen,
Toronto, ON, Canada), using Silenfect transfection reagent (Bio-Rad,
Mississauga, ON, Canada).
Western blotting
Western blot analysis was performed as described previously (Li et al.,
2008). The list of antibodies is available in the Supplementary
Methods online.
Cell invasion assay and zymography
Boyden chamber invasion assay and zymography were performed as
previously described (Li et al., 2008).
FACS analysis
FACS analysis was performed as described before (Khosravi et al.,
2014).
Cell proliferation assay
Cell proliferation was determined with the sulforhodamine B assay as
previously described (Khosravi et al., 2014).
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